Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy

Cellectis SA (NASDAQ: CLLS ) is a company I've expressed tentative optimism about their upcoming data updates in 2025. In particular, the company is positioning itself to truly begin answering questions about their pipeline. Today, I wantI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get b ...